EUCTR2004-000537-11-IT
Active, not recruiting
Not Applicable
An open label, multi-center study on the efficacy and safety of IgPro10 in patients with chronic immune thrombocytopenic purpura ITP
ZLB BEHRING0 sites60 target enrollmentFebruary 28, 2007
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ZLB BEHRING
- Enrollment
- 60
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
An open-label, multicenter study on the efficacy and safety of IgPro10 in patients with chronic immune thrombocytopenic purpura (ITP)Immune thrombocytopenic purpura (ITP) is the most common autoimmune disease. It is a bleeding disorder characterized by decreased counts of circulating platelets and normal or increased numbers of megakaryocytes in the bone marrow.EUCTR2004-000537-11-DEZLB Behring AG60
Active, not recruiting
Not Applicable
A multicenter, open-label study on the efficacy, cycle control and safety of a contraceptivevaginal ring delivering a daily dose of 150 µg of Nestorone(R) and 15 µg of ethinyl estradiol (150/15 NES/EE CVR)As the trial is intended to investigate a new contraceptive medicinal product, the study subjects included are not characterized by a specific medical condition.MedDRA version: 8.1Level: PTClassification code 10010808Term: ContraceptionEUCTR2005-004978-25-HUInternational Committee for Contraception Research of the Population Council2,200
Active, not recruiting
Not Applicable
A multicenter, open-label study on the efficacy, cycle control and safety of a contraceptivevaginal ring delivering a daily dose of 150 µg of Nestorone(R) and 15 µg of ethinyl estradiol (150/15 NES/EE CVR)As the trial is intended to investigate a new contraceptive medicinal product, the study subjects included are not characterized by a specific medical condition.MedDRA version: 8.1Level: PTClassification code 10010808Term: ContraceptionEUCTR2005-004978-25-SEInternational Committee for Contraception Research of the Population Council2,200
Active, not recruiting
Not Applicable
A multicenter, open-label study on the efficacy, cycle control and safety of a contraceptivevaginal ring delivering a daily dose of 150 µg of Nestorone(R) and 15 µg of ethinyl estradiol (150/15 NES/EE CVR)As the trial is intended to investigate a new contraceptive medicinal product, the study subjects included are not characterized by a specific medical condition.MedDRA version: 8.1Level: PTClassification code 10010808Term: ContraceptionEUCTR2005-004978-25-FIInternational Committee for Contraception Research of the Population Council2,200
Completed
Phase 4
Multicenter, open-label study to assess the effects of Certolizumab Pegol on the reduction of anterior uveitis flares in axial spondyloarthritis subjects with a history of anterior uveitis (C-view)anterior uveïtis flares in axial spondyloarthritiseye inflammation in spondyloarthritis1001591910023213NL-OMON46252CB Biopharma SPR10